Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Fibrosis 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Sampling Studies × Thoracic × Clear all
NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡